May 10, 2022

Public workspaceDonor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC

DOI
dx.doi.org/10.17504/protocols.io.b49tqz6n
  • 1University of California, San Diego
  • Human BioMolecular Atlas Program (HuBMAP) Method Development Community
    Tech. support email: Jeff.spraggins@vanderbilt.edu
Valentina Stanley
Icon indicating open access to content
QR code linking to this content
DOI: dx.doi.org/10.17504/protocols.io.b49tqz6n
Document Citation: Valentina Stanley, Mana Parast, Louise C. Laurent 2022. Donor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC. protocols.io https://dx.doi.org/10.17504/protocols.io.b49tqz6n
License: This is an open access document distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Created: February 17, 2022
Last Modified: May 10, 2022
Document Integer ID: 58387
Keywords: HuBMAP, UCSD Female Reproductive TMC
Abstract
This document outlines the inclusion and exclusion criteria for donors of placenta, fallopian tubes and uterine myometrium in the Human BioMolecular Atlas Program (HuBMAP).
HuBMAP Donor Selection Criteria for Inclusion in the UCSD Female Reproductive TMC
INCLUSION CRITERIA
  • Healthy pregnant women without maternal comorbidities or current pregnancy complications or previous history of poor obstetrical outcome
  • Patients 18 years or older
  • Patients planning to deliver at a UCSD Medical Center
EXCLUSION CRITERIA
  • Patients under the age of 18 years
  • Patients with Tuberculosis (TB), HIV, Hepatitis B or Hepatitis C
  • Patients currently institutionalized for a psychiatric disorder, have intellectual disability or who are currently incarcerated
  • Patients with abnormal serum analytes, as defined by one or more of the following: Low PAPP-A (<0.30), High AFP (>2.5), High HCG (>3.0), High Inhibin (>2.0), Low UE3 (<0.30)
  • Patients with poor pregnancy outcome as defined by severe preeclampsia, placental abruption, PPROM, short cervix, eclampsia, HELLP syndrome, intrauterine growth restriction (newborn < 5th percentile for gestational age), or stillbirth (>16 weeks’ gestation), or intrauterine fetal death with placental involvement
  • Patients with maternal medical comorbidities as defined by having any of the following: gestational hypertension, renal disease, Type 1 or Type 2 diabetes, antiphospholipid antibody syndrome, lupus, or other autoimmune disorders
  • Patients with any other fetal complication including, but not restricted to, fetal structural anomalies or genetic abnormalities
  • Any other pregnancy or maternal complication including, but not restricted to, structural placental membrane or cord abnormalities, multifetal gestation, placenta accreta spectrum, etc.